Efficacy and safety of niraparib in platinum-sensitive recurrent ovarian cancer: retrospective observational study in a tertiary hospital.

Elena Prado-MelPaloma Suárez-CasillasLupe Rodríguez-de FranciscoPurificación Estévez-GarcíaRocío Jiménez-Galán

Published in: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2024)

This real-world study showed that maintenance niraparib in PSROC patients had effectiveness and safety profiles consistent with clinical trials and other observational studies. Median PFS and OS were comparable to previous reports, and most adverse events were manageable with dose modifications. The results support the use of niraparib as a maintenance therapy option in this patient population.

Keyphrases

clinical trial
end stage renal disease
ejection fraction
chronic kidney disease
newly diagnosed
peritoneal dialysis
case report
randomized controlled trial
mesenchymal stem cells